Mandate

Vinge advises Calliditas Therapeutics in connection with Asahi Kasei Corporation’s public takeover offer

On 28 May 2024, Asahi Kasei Corporation announced a public takeover offer to the shareholders and holders of American Depositary Shares in Calliditas Therapeutics AB (publ) (”Calliditas Therapeutics”) to acquire all shares and American Depositary Shares (each representing two shares) in Calliditas Therapeutics.

Calliditas Therapeutics is a biopharma company listed on Nasdaq Stockholm and on the Nasdaq Global Select Market in the US focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs. The total value of the offer amounts to approximately SEK 11,164 million, based on the total number of outstanding shares in Calliditas Therapeutics. Vinge advises Calliditas Therapeutics.

Vinge’s team has mainly consisted of Dain Hård Nevonen, Linnéa Sellström, William Kåge and Benjamin Vafaeian (Capital Markets and Public M&A) and Daniel Wendelsson (FDI).

Related

Vinge has represented Inflexion in connection with the acquisition of Mecenat

Vinge has represented Inflexion in connection with the acquisition of the Mecenat group from IK. The acquisition of Mecenat is the first investment made through Inflexion's new Enterprise Fund VI, and Inflexion's first acquisition in Sweden.
January 14, 2025

Vinge has advised the sellers in connection with the sale of Färskvaruhuset i Göteborg AB

Färskvaruhuset i Göteborg AB is a Swedish nationwide supplier to the retail sector within meat and poultry as well as charcuterie and delicatessen products. The acquirer was the international food trading company BPI A/S, headquartered in Denmark.
January 13, 2025

Vinge has advised the seller in conjunction with the sale of Lundby Plåt Aktiebolag

Lundby Plåt Aktiebolag provides services within sheet metal work. The acquirer was the Gothenburg based contracting and construction services company, Göfast Gruppen AB.
January 13, 2025